The pathomorphology of urolithiasis and the chemical analysis of the stones by x-ray diffraction and infrared spectroscopy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background: Stones consist of the organic, inorganic and amorphous part. The factors that affect the formation of stones can be divided into two categories; 1). Those that are in the urine and form the crystalline nucleus, agglomeration, which includes proteins, salts, glycoprotein’s, phospholipids, and 2). Changes in cell surface leading to crystal adhesion to epithelial cells. Objective: The purpose of this study was to determine the composition of uroliths (stones), nucleus, envelope, core component and stone layer component. Material and Methods: The research was conducted with patients of the Urology Clinic, University Clinical Center of Kosovo, in Prishtina. The work was prospectivein our research were included 102 patients. After the intervention: endoscopic or surgery, we took the stone and did the chemical analysis of the stones with the method: X-ray diffraction and infrared spectroscopy. This will determine the components of the stones and their types. From the statistical parameters, the structure index, arithmetic mean, and standard deviation were calculated. Qualitative data testing was done with X2-test or Fisher test. Quantitative data testing with T-test., Test verification was done with a reliability rate of 99.7% (p<0.01) and a reliability of 95% (p<0.05). Results: Our study included66.7% male and 33.3%female. With X2-test we gained a difference with statistically significant significance in the number of cases by gender (X2=11.3, p=0.001). The age group most attacked is 40-49years. The chemical component of stone patients was: 58.8% Calcium oxalate monohydrate, 14.7% Calcium Phosphate, 10.8% Magnesium ammonium phosphate, 5.9% Calcium oxalate dihydrate, 4.9% Uric acid, 2.9% Cystinic, 1.0% Ammonium hydrogen urate and brush 1.0%. We have the group of children who are 8 cases or 7.84%. The chemical composition; Calcium oxalate monohydrate 2.94%, Cystinic; 1.96%, Calcium Ox.Dihydrate; 0.98%, Magnesium ammonium phosphate; 0.98%, uric acid; 0.98%. Conclusion: X-ray diffraction analyzes the crystalline components of the stone, while infrared spectroscopy is more sophisticated to identify non-crystalline materials, including amorphous substances and fat. In our adult research, calcium oxalate monohydrate, calcium phosphate stones appear more often, while in children, calcium oxalate monohydrate. The most common stone nucleus analysis is Ammonium hydrogen urate.

Full Text

Restricted Access

About the authors

Nuraj Petrit

University Clinical Center of Kosovo

Email: petrit.nuraj@uni-pr.edu
MD, MS, PhD, Department of Urology, University Clinical Center of Kosovo, Faculty of Medicine, University of Prishtina Prishtina, Republic of Kosovo

Beqiri Agron

University Clinical Center of Kosovo

Department of Urology, University Clinical Center of Kosovo, Prishtina Prishtina, Republic of Kosovo

References

  1. Tzelves L, Tmk C, Skolarikos A. European Association of Urology Urolithiasis Guidelines: Where Are We Going? European Urology Focus. 2020 Oct 1.
  2. Arnett T.R. Extracellular pH regulates bone cell function. The Journal of nutrition. 2008;138(2):415S-8S.
  3. Seitz C, Liatsikos E, Porpiglia F, Tiselius HG, Zwergel U. Medical therapy to facilitate the passage of stones: what is the evidence? European urology. 2009;56(3):455-71.
  4. Pearle M.S., Calhoun E.A., Curhan G.C., Urologic Diseases of America Project. Urologic diseases in America project: urolithiasis. The Journal of urology. 2005;173(3):848-57.
  5. Lee S.C, Kim Y.J, Kim T.H., Yun S.J., Lee N.K., Kim W.J. Impact of obesity in patients with urolithiasis and its prognostic usefulness in stone recurrence. J Urol. 2008;179(2):570-74.
  6. Devuyst O, Pirson Y. Genetics of hypercalciuric stone forming diseases. Kidney international. 2007;72(9):1065-72.
  7. Agrawal M, Gupta M, Gupta A, Agrawal A, Sarkari A, Lavania P. Prospective randomized trial comparing efficacy of alfuzosin and tamsulosin in management of lower ureteral stones. Urology. 2009;73(4):706-9.
  8. Griwan MS, Singh SK, Paul H, Pawar DS, Verma M. The efficacy of tamsulosin in lower ureteral calculi. Urology annals. 2010;2(2):63.
  9. Resim S, Ekerbicer H, Ciftci A. Effect of tamsulosin on the number and intensity of ureteral colic in patients with lower ureteral calculus.International journal of urology. 2005;12(7):615-20.
  10. Hollingsworth JM, Rogers MA, Kaufman SR, Bradford TJ, Saint S, Wei JT, Hollenbeck BK. Medical therapy to facilitate urinary stone passage: a metaanalysis. The Lancet. 2006;368(9542):1171-9.
  11. Gillenwater JY, editor. Adult and pediatric urology. Lippincott Williams & Wilkins; 2002.
  12. Pedro RN, Hinck B, Hendlin K, Feia K, Canales BK, Monga M. Alfuzosin stone expulsion therapy for distal ureteral calculi: a double-blind, placebo controlled study. The Journal of urology. 2008;179(6):2244-47.
  13. Bistory M, Galanakis E. Epicurus death. World J Urol 2004;22:466-469.
  14. Eknoyan G. History of urolithiasis.Clin Rev Bone Min Metab, 2004; 2:177-185.
  15. Srivastava T, Winston MJ, Auron A, Alon US. Urine calcium/citrate ratio in children with hypercalciuric stones. Pediatric research. 2009;66(1):85-90.
  16. Griffin DG. A review of the heritability of idiopathic nephrolithiasis. Journal of clinical pathology. 2004;57(8):793-96.
  17. Garlick PJ. Protein requirements of infants and children: Nestle NutrWorkshop Ser Pediatr Preogram 2006;58: 39-47.
  18. Pecoits-Filho R. Dietary protein intake and kidney disease in Western diet. Nutrition and Kidney Disease: A New Era. 2007;155:102-12.
  19. Calvert RC, Burgess NA. Urolithiasis and obesity: metabolic and technical considerations. Current opinion in urology. 2005;15(2):113-7.
  20. Pearle MS, Calhoun EA, Curhan GC, Urologic Diseases of America Project. Urologic diseases in America project: urolithiasis. The Journal of urology. 2005;173(3):848-57.
  21. Lingeman JE. Surgical management of upper urinary tract calculi. Campbell-Walsh Urology. 2006:1431-507.
  22. Singh SK, Pawar DS, Griwan MS. Tamsulosin as an expulsive therapy for lower ureteric calculus after extra corporeal shock wave lithotripsy: a randomized controlled study. Nephro-Urology Monthly 2011;3(1):62-68.
  23. Singh SK, Pawar DS, Griwan MS, Indora JM, Sharma S. Role of tamsulosin in clearance of upper ureteral calculi after extracorporeal shock wave lithotripsy: a randomized controlled trial. Urology journal. 2011; 8(1):14.
  24. Marshall LS. Urinary stone disease in: Amend WJC Jr, Barbour S, Baskin LS, Berger TG, Bloom AL, Bretan PNJr. et al. (editors). Smith’s urology. 16th ed New York: McGraw Hill. 2004. P.256-90.
  25. Gillenwater JY, editor. Adult and pediatric urology. Lippincott Williams & Wilkins; 2002.
  26. Khan SR. Crystal-induced inflammation of the kidneys: results from human studies, animal models, and tissue-culture studies. Journal of Clinical and Experimental Nephrology. 2004;8(2):75-88.
  27. Autorino R, De Sio M, Damiano R, Di Lorenzo G, Perdona S, Russo A, Quarto G, Cosentino L, D’Armiento M. The use of tamsulosin in the medical treatment of ureteral calculi: where do we stand?. Urological research. 2005;33(6):460-4.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2021 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies